Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00757666 · ClinicalTrials.gov registry record · NA
APPROPRIATE - Rate Adaptive Pacing Sensor
A NA study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 566
- Enrollment target
NCT00757666: Clinical Trial NA study, sponsored by Boston Scientific Corporation.
NCT00757666 is a NA study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 566 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00757666, a NA study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 566 participants
- Enrollment target
Study Summary
The APPROPRIATE study will compare differences in functional capacity (peak VO2) between chronotropically incompetent patients randomized to receive rate responsive pacing driven by either the minute ventilation (respiration-based) sensor or an accelerometer (motion-based).
Primary Outcome
The APPROPRIATE Study compared differences in functional capacity (peak VO2) between CI patients randomized to receive rate responsive pacing driven by either the minute ventilation (respiration-based) sensor or by an accelerometer (motion-based) sensor. The mean change in functional capactity will be compared against baseline; changes from baseline will be measured.
Interventions
- DEVICE Rate adaptive pacemaker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 566 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-01 |
| Phase | NA |
Why NCT00757666 stopped before completion
NCT00757666 is an interventional study that assigns participants to a tested intervention. The registered 566 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which Rate adaptive pacemaker is the first listed.
NCT00757666 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00757666 about?
NCT00757666 is a clinical study titled "APPROPRIATE - Rate Adaptive Pacing Sensor". The APPROPRIATE study will compare differences in functional capacity (peak VO2) between chronotropically incompetent patients randomized to receive rate responsive pacing driven by either the minute ventilation (respiration-based) sensor or an accelerometer (motion-based).
What is the current status of trial NCT00757666?
This trial is currently terminated. It is a NA study. The enrollment target is 566 participants. The study started on 2008-12. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00757666?
The interventions under investigation include: Rate adaptive pacemaker (DEVICE).
Who is sponsoring clinical trial NCT00757666?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00757666's enrollment target sits among peer trials
566 180th of 2000 higher than 1,821 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05472441 · 568 participants · NA
Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia